Related Experiment Videos
Frape-1 and Frape-3: two different recombinant retroviruses encoding the same human marker gene
Y Y Ng1, P Veenhuizen, H Lokhorst
1Departments of Immunology and Hematology, Utrecht University Hospital, The Netherlands.
Cancer Gene Therapy
|May 16, 2000
Summary
New retroviral vectors enable tracking of gene-modified cells in vivo. These vectors use a neutral marker gene, the truncated human nerve growth factor receptor, for easy identification via polymerase chain reaction analysis.
Area of Science:
- Biotechnology
- Gene Therapy
- Molecular Biology
Background:
- Retroviral gene therapy requires methods for tracking transduced cells.
- Gene marking of hematopoietic cells aids in vivo monitoring.
- Neutral, non-immunogenic marker genes are crucial for in vivo applications.
Purpose of the Study:
- To design and construct novel retroviral vectors for tracking distinct cell populations.
- To develop vectors encoding a neutral, non-immunogenic marker gene.
- To facilitate in vivo gene therapy toxicity studies and relapse source determination.
Main Methods:
- Designed and constructed two retroviral vectors (Frape-1 and Frape-3) encoding a truncated human nerve growth factor receptor.
- Modified vectors to differ at the DNA level with unique restriction sites for polymerase chain reaction (PCR) detection.
- Transduced cell lines and primary CD34+ cells with the developed vectors.
Main Results:
- Successfully transduced cell lines and primary CD34+ cells using Frape-1 and Frape-3 vectors.
- Demonstrated that transduced cells can be distinguished using PCR and vector-specific restriction sites.
- Confirmed the neutral and non-immunogenic nature of the truncated nerve growth factor receptor marker.
Conclusions:
- The Frape-1 and Frape-3 vectors are effective tools for gene marking in hematopoietic cells.
- These vectors allow for the selection and tracking of transduced cell populations.
- The developed vectors will be valuable for in vivo gene therapy research and clinical applications.